Depending on the application, a field instrument is required to measure and control different automation processes. This is why Endress+Hauser's field instruments use different measuring principles to operate reliably and accurately in any situation.
Endress + Hauser provides process automation solutions for pharmaceutical companies, supporting projects ranging from pilot plants to fully automated commercial-scale facilities.
The company helps streamline production, maintain quality and optimise performance while keeping to clients’ stringent schedules. It also uses the latest in technological innovations to help clients comply with good manufacturing practice (GMP) regulations throughout the product lifecycle.
Endress + Hauser’s instruments are designed to ASME-BPE standards.
Process measurement instrumentation and services
Endress + Hauser helps provide input to user requirement specifications, deliver key documentation, undertake performance testing and offer support for products, applications and services with full traceability.
The company offers a wide range of consistently high-quality process measurement and instrumentation products, services and solutions to reduce costs throughout the supply chain. Its products meet good automated manufacturing practice (GAMP) and International Society for Pharmaceutical Engineering (ISPE) guidelines.
Endress+Hauser is a globally qualified partner that designs and develops innovative process measurement instrumentation, solutions and services in accordance with good practice (GxP) guidelines and optimised to client requirements.
The firm’s devices offer a comprehensive range of hygienic and aseptic process connections such as Triclamp and Varivent to avoid zones where bacteria could develop, affecting product quality.
Meeting life science industry standards
Endress+Hauser operates two Centers of Competence that provide expertise in life sciences projects. The company employs a dedicated GxP-certified life science team that has been expertly trained and that understands the challenges of the life sciences industry.
Endress+Hauser‘s products meet industry standards such as ASME BPE, GAMP 5, US Food and Drug Administration (FDA) listed materials for wetted parts (21 CFR part 177), 3-A authorisation and the European Hygienic Engineering and Design Group (EHEDG), as well as have certificates for sterilise-in-place (SIP) cycles up to 150°C, materials certificates according to EN-10204, calibration certificates and standards of practice (SOP) for calibration and maintenance.
The company’s experience has been gained through the development of long-term relationships with its customers, where it aims to improve efficiency, innovation and compliance.
Documentation and traceability of process measurement instrumentation
Endress+Hauser provides a comprehensive range of documentation, certificates, instructions and procedures that are GxP compliant and are mandatory for design qualification (DQ), installation qualification (IQ), operation qualification (OQ) and performance qualification (PQ).
The company also provides technical support for writing (SOP) and other procedures according to the GAMP5.
Endress+Hauser works closely with clients throughout the entire lifecycle of your project, from the planning and project phase right through to the operational phase.
This includes the planning, specification, design, configuration, coding, verification, reporting and release of online and offline systems for product lifecycle.
Pre-engineered solutions and calibration management software
Endress + Hauser’s pre-engineered solutions and calibration management software (CMS) provide compliant solutions for, as an example, the implementation of the 21 CFR Part 11 for pharmaceuticals, biotechnology, cosmetics, food and beverages, and fine chemistry.
The iTHERM TrustSens TM371 and TM372 compact hygienic thermometer is designed for applications in the life sciences and food and beverage industries that require seamless compliance to FDA regulations and/or GMP rules
Klaus Köhler's task is to bring Endress + Hauser customers as close as possible to the company to develop the right instruments, solutions, and services that provide the most value.
Our service expert talks about the importance of calibration in the life sciences industry and how Endress+Hauser can help you optimize your calibration intervals and manufacturing continuity.
Switzerland has a sense of tradition and passion for technology. Endress + Hauser combines both. It began as pioneers of electronic sensor technology in 1953.
This paper will explain how in-situ verification technologies such as Heartbeat Technology can be used even in strictly regulated industries and be a part of a CFR part 11 compliant system.
Raman technology solves many process challenges for a wide range of upstream and downstream biopharmaceutical applications.
To meet regulatory requirements, users must perform traceable calibrations on instruments to maintain product quality.
What was once a laborious process is getting easier, thanks to modern sensors and calibration procedures.
In April 2018, global animal health company Zoetis began building an animal vaccine manufacturing and research complex in Suzhou, China.
In July 2008, Gedeon Richter, one of Hungary's largest pharmaceutical companies, started building a facility for the development and manufacture of biopharmaceutical products in Debrecen.
Cordis Corporation was established in Miami in Florida, US in 1959. The company is a subsidiary of the pharmaceutical major Johnson & Johnson.
Endress+Hauser BioSense to develop equipment and methods for fast molecular analyses
Endress+Hauser has achieved 76 out of 100 points in the international EcoVadis sustainability rating, four more than in the previous year. The Group achieved a ranking in the top group for the fifth year in a row in 2021 and is now among the top one percent of the companies compared.
Around 35 Open Integration programme partners gathered together at Endress+Hauser in Reinach, Switzerland, to share their experiences and thoughts for the first time.
Endress+Hauser experienced strong growth across all regions, sectors and product areas in 2018. The ongoing digitalisation of the industry and positive development on the international markets provided impetus. The Group increased sales and profits, invested heavily and created hundreds of jobs worldwide.
In industrial process measurement and automation, demand is steadily rising for simple, reliable and maintenance-free instruments in a pocket-sized format.
SAP and Endress+Hauser have agreed to cooperate for the development of Industrial Internet of Things (IIoT) applications for the process industry.
In the food and life sciences industries, very small measurements must be made with a high degree of accuracy.
Do you have measuring points where installation space is restricted? Do you require a high degree of measured value availability for your production process? If so, then Endress+Hauser have the perfect transmitter for you: the Liquiline Compact CM82.
Endress+Hauser invested more than €10.4m in a state-of-the-art production facility at its location in Nesselwang, Germany.
In 2014, Endress+Hauser filed more patents than ever before due to their range of innovative products.
Endress+Hauser has opened a new 80,000ft² state-of-the-art Customer Center in Greenwood, Indiana, US.
When it comes to the early identification of new technologies, Endress+Hauser is a clear leader, as shown by an award given by the renowned Fraunhofer Institute.
Changes are taking place to the supervisory board of the Endress+Hauser Group. The annual general meeting elected Hans-Peter Endress, Thomas Kraus and Antonietta Pedrazzetti as new members of the group's controlling body. In turn, Dr George A Endress, Dr Hans Fünfschilling and Willi Ruesch have duly retired from the board.
Endress+Hauser has acquired additional shares in German-based Analytik Jena AG and exceeded the reportable threshold of 50% of the voting rights. The Group now owns 50.37% of the shares.
The Endress+Hauser Group increased its net sales by approximately 7% to more than €1.8bn in the 2013 financial year. In terms of operating profit, profit before taxes and net income, the company also showed an improvement on the previous year.